Search

The in vitro susceptibility of 225 clinical isolates of yeasts to ciclopiroxolamine (CPO) was compared with that of clotrimazole, econazole, ketoconazole, miconazole, tioconazole, fluconazole, itraconazole and nystatin using a standardized agar diffusion method (NeoSensitabs®). Two hundred and eight strains of yeasts comprising 16 species of Candida and 22 strains belonging to other yeast genera were tested. One strain (0.4%) was resistant, four strains (1.8%) of intermediate susceptibilty and 220 strains (97.3%) susceptible to CPO. More strains were suscepible to CPO than to the other antifungals studied. Susceptibility patterns of antifungal agents were not linked to species. The in vitro antifungal susceptibility profile of CPO was better than topical azole derivatives or fluconazole and itraconazole against a wide variety of clinically important yeasts. [Copyright &y& Elsevier]

Introduction and aim. Ciclopirox has been treating fungal infections for decades. Recent studies suggest ciclopirox may be repurposed to treat cancer, viral infections, and neurological disorders. Ciclopirox exerts anticancer by inhibiting multiple pathways of cancer cell growth and survival and anti-viral actions by reducing viral replication and altering the host immunological response to viral infection. Recent research suggests that ciclopirox may protect against neurodegenerative illnesses including Alzheimer's and Parkinson's. This narrative review shows ciclopirox's potential to treat cancer, viral infections, and neurological diseases. Material and methods. Current relevant research publications focused on ciclopirox and its repurposing medicinal potential, therefore a well-designed technique was used to find them. „Ciclopirox", „Anti-fungal", „Anti-cancer", „Repurposing", and „Therapeutic potential" were used to search PubMed, Web of Science, EMBASE, and Google Scholar. Analysis of literature. Ciclopirox may reduce oxidative stress and inflammation, which may cause several illnesses. Overall, the repurposing of ciclopirox for the treatment of cancer, viral infections, and neurodegenerative disorders represents a promising avenue of research that warrants further investigation. Conclusion. It was concluded that CPX and olamine derivatives as outstanding antifungal medications, as well as provide information on ongoing research to use them for other illnesses. [ABSTRACT FROM AUTHOR]

Context: Ciclopirox olamine (CPO) is indicated in the treatment of vaginal fungal infections. The frequent and large dosing of available vaginal CPO creams gives rise to poor compliance amongst females. In such a situation a delivery system capable of providing sustained release of CPO is warranted and can be realized through incorporation of its liposomal formulation into a mucoadhesive gel base. The liposomal formulation would offer sustained release whereas mucoadhesive gel would prolong the contact with vaginal wall; thus avoiding frequent and large dosing. Objective: The present study aimed at investigating mucoadhesive liposomal CPO gel for vaginal use. Method: The study embarked on evaluating liposomal CPO and its Carbopol 974®P gel for stability at vaginal pH, release profile, rheological characteristics, mucoadhesive behavior and finally antifungal activity. Results: The results revealed that CPO liposomes were stable at vaginal pH; its Carbopol gel released 58.75 ± 6.4% of CPO at the end of 24 h which suggested sustained release. Rheology via viscometric, oscillatory stress sweep and oscillatory frequency sweep testing of the gel, studied at different temperatures and under different dilutions with vaginal fluid simulant testified pseudoplastic behavior of the gel. It also pointed towards the predominance of elastic behavior of the gel at all the dilutions. The gel exhibited good mucoadhesivity to sheep vaginal tissue. Furthermore, CPO entrapped in liposome too displayed antifungal activity. Conclusion: The study undertaken recommended Carbopol 974®P gel loaded with CPO liposomes as a potential delivery system for treatment of fungal vaginal infections. [ABSTRACT FROM AUTHOR]